The 2017 American College of Cardiology/American Heart Association Blood Pressure Treatment Guidelines reduced the systolic blood pressure (SBP) level that defines hypertension from 140 to 130 mm Hg.
1 However, while guideline recommendations focus on the cut point at which there is likely to be a net benefit to pharmacologic treatment, many individuals classified as having low risk based on traditional atherosclerotic cardiovascular disease (ASCVD) risk factors have subclinical atherosclerosis as measured by the presence of coronary artery calcium and may therefore not truly be at the lowest risk.
2-5